Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: Variagenics Crouch is Out; Deltagen Board Gets Gore Advisor; Genaissance Promotes Vovis

NEW YORK, May 1 - Nanogen said yesterday it has added Robert Whalen to its board of directors.


Whalen will guide Nanogen as it moves into molecular diagnostics, board chair Howard Birndorf said in a statement.


Whalen was previously president, chief executive officer, and director of Unilab, a major California clinical lab service company.


Prior to that, he was executive vice president and chief operating officer of Scripps Clinic.


Nanogen also said that Xcel board chair Cam Garner will not seek re-election after his current term expires in June.



Zyomyx yesterday said it has hired Hirdey Bhathal as vice president of corporate development.


Bhathal will be responsible for business development and sales of the company's protein chip products and technologies.


Bhathal is a veteran of Agilent and LI-COR Biotechnology, where he sold microarray and sequencing technology.



Biotechnology law expert and former Al Gore domestic-policy advisor David Beier will join Deltagen's board of directors, the company said on April 26.


Beier is partner in the Washington office of Hogan & Hartson, where he focuses on biotechnology, pharmaceuticals, telecommunications, and the Internet.


During the Clinton administration, Beier was the chief domestic policy advisor for the vice president, where he chaired the Task Force on Electronic Commerce and helped formulate policy on intellectual property, science, technology, agricultural, energy, and trade.


Beier was previously vice president of government affairs for Genentech, and before that counsel to the judiciary committee of the US House of Representatives.



Pharmacogenomics firm Variagenics said on April 25 that its president and CEO Taylor Crouch had resigned.


Crouch, 41, became president and CEO in April 1999.


Variagenics promoted vice president of marketing and business development Joseph Mohr  to president and chief business officer.


Company chief financial officer Richard Shea, 49, will add the role of chief operating officer.



Genaissance Pharmaceuticals said on April 24 that it had promoted Senior Vice President Gerald Vovis to executive vice president and promoted Medical Director Carol Reed to executive director of medical affairs.


Vovis, 59, will be involved in investor and analyst outreach and will retain his role as chief technology officer at the company.


Reed, 48, oversees clinical operations, clinical trials, data management, biostatistics, and regulatory affairs. 



Bioinformaticist (and Genome Technology columnist) Nat Goodman has taken a position as senior research scientist at the Institute for Systems Biology in Seattle.


Goodman was most recently senior vice president at the bioinformatics consulting firm 3rd Millennium.


He helped found the Whitehead Center for Genome Research and also led a bioinformatics marketing team for Compaq.



Zyomyx director and former Albert Einstein College of Medicine molecular genetics chair Raju Kucherlapati is now scientific director of the new Harvard-Partners Center for Genetic and Genomic Research.


At Einstein, Kucherlapati lead efforts to map human chromosome 12. He is a member of the National Advisory Council for Human Genome Research, a co-founder and director of both Millennium Pharmaceuticals and Cell Genesys, and serves on the boards of Abgenix, Millennium, and Valentis.


He will continue work on chromosome 12 at Harvard and is studying two genetic disorders related to chromosome 22 deletions.


The new center, currently under development, is backed by Harvard Medical School, Massachusetts General Hospital, and Brigham and Women's Hospital.



The British informatics company InforSense said on April 19 that it had appointed Paul Davie as president and chief operating officer.


He will be responsible for business operations, particularly marketing and sales.


Davie was previously European general manager and senior director of consultancy services for Accelrys.


InforSense, based in London, develops discovery informatics software.



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kat McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics that runs every Wednesday.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.